Google Translate: Financial Associated Press (Shenzhen, reporter Ding Rong), Malaysian listed company YONGTAIBERHAD recently announced that the company has reached cooperation with Shenzhen Kangtai Biological Products Co., Ltd. and KLINSELSDNBHD to promote Kangtai Bio-New Crown inactivated vaccine in Malaysia to carry out phase III clinical trials . After the phase III clinical trial is successfully concluded or emergency use rights are obtained in Malaysia, the company will have the exclusive commercialization rights. The two parties plan to cooperate with about 100 million doses, a five-year vaccine procurement plan.
A person close to Kangtai Biologicals (300601.SZ) said: "At present, Kangtai Biologicals Covid-19 vaccine research and development continues to advance. This time, it is cooperating with Malaysia YONGTAIBERHAD to jointly promote the international multi-center phase III clinical trial of the new coronavirus inactivated vaccine."
Regarding the new coronavirus inactivated vaccine (Vero cell), Kangtai Biotechnology received a drug clinical trial approval document issued by the National Medical Products Administration in September this year. After review and review by a special expert group, the product was approved for clinical trials in an emergency. The indication is Prevent new coronavirus pneumonia caused by new coronavirus infection. Information from the China Clinical Trial Registration Center shows that the vaccine has entered the phase II clinical trial in October.
It is worth mentioning that in addition to the independently developed inactivated vaccine for the new crown, Kangtai Biotech also cooperates with AstraZeneca in the ChAdOx1 adenovirus vector vaccine. The viral vector COVID-19 vaccine developed by the company and AstraZeneca is currently in the phase III clinical trial. It is a rapidly progressing COVID-19 vaccine project in the world. It is expected to be used urgently in Europe and the United States by the end of the year. It is expected to be introduced to China in the future. The time for domestic clinical trials is expected. It will also be shortened. In addition, Kangtai Biological also deployed recombinant VSV virus vector vaccine.
The Financial Association stated: The content of the article is for reference only and does not constitute investment advice. Investors operate accordingly at their own risk.
AstraZeneca in deal with Kangtai Bio to supply potential COVID-19 vaccine in China - BEIJING, Aug 6 (Reuters) - AstraZeneca PLC has signed an exclusive framework agreement with China’s Shenzhen Kangtai Biological Products to supply its COVID-19 vaccine candidate in mainland China, the British pharmaceutical giant said on Thursday.
To meet market demand in China, Shenzhen Kangtai is obliged to make sure it has an annual production capacity of at least 100 million doses of the experimental shot AZD1222, which AstraZeneca co-developed with researchers at Oxford University, by the end of this year, and a capacity of at least 200 million doses by the end of next year, AstraZeneca said in a statement on the Chinese social media site WeChat.
The two companies will also explore the possiblity of cooperation on the vaccine candidate in other markets, AstraZeneca said.
Bursa expected to ride on Santa Claus rally next week December 26, 2020 10:28 am +08 KUALA LUMPUR (Dec 26): Bursa Malaysia is expected to rebound strongly next week, with the benchmark FTSE Bursa Malaysia KLCI (FBM KLCI) set to test the psychological level of 1,700, amidst window-dressing activities and improved market sentiment.
Inter-Pacific Asset Management Sdn Bhd chief executive officer Datuk Dr Nazri Khan Adam Khan said the key index is poised to march into the new year on a high note, riding on the ‘Santa Claus’ rally as investors turn bullish towards year-end.
“Traditionally, the last week of December and the first week of new year are the strongest weeks of the year, therefore I believe KLCI will move higher between 1,680 and 1,700,” he told Bernama.
He said the market sentiment would be positive due to rising commodity prices, stronger ringgit versus the US dollar, optimism over COVID-19 vaccine distribution in Malaysia next year, as well as a smooth free trade deal between Britain and the European Union.
Nazri Khan said the overall market volume would be thin in the next two weeks as a majority of institutional buyers would be inactive due to the holidays, but the market momentum would be supported by buying in the small-capitalisation stocks.
Bursa Malaysia started the week on a weak note as investors’ sentiment was affected by worries over the global economy outlook, and the risk appetite continued to drift away the following day on mounting concerns over the new COVID-19 strain in the United Kingdom and the weak oil prices.
Nevertheless, the local market snapped its losing streak on Wednesday as bargain-hunting emerged ahead of the long weekend break, on the promising news of COVID-19 vaccine delivery by pharmaceutical company, AstraZeneca, which is expected to take place in the first half of 2021.
However, the FBM KLCI reversed its gains on Thursday due to profit taking amidst the cautious market sentiment, before taking a break for Christmas on Friday.
On a Friday-to-Thursday basis, the benchmark FBM KLCI decreased 11.32 points to 1,641.17 on Thursday from 1,652.49 on Friday last week.
On the scoreboard, the FBM Emas Index fell 79.57 points to 11,810.92, the FBMT 100 Index erased 80.12 points to 11,569.93, the FBM 70 contracted 106.06 points to 15,112.54, and the FBM Emas Shariah Index reduced 51.29 points to 13,283.18.
However, the FBM ACE Index surged 209.65 points to 10,657.3.
Sector-wise, the Plantation Index bagged 57.48 points to 7,407.28, the Industrial Products and Services Index added 0.2 of-a-point to 175.89, while the Financial Services Index tumbled 164.63 points to 15,260.37.
The Energy Index shed 28.58 points to 879.47, the Healthcare Index gave up 29.95 points for 3,672.36, while the Technology Index trimmed 0.46 of-a-point to 67.41.
Weekly turnover decreased sharply to 28.99 billion units worth RM14.05 billion from 50.37 billion units worth RM26.15 billion last week.
Main Market volume plummeted to 17.26 billion shares valued at RM10.7 billion versus 32.40 billion shares valued at RM22.03 billion previously.
Warrants turnover, however, increased to 7.85 billion units worth RM364.77 million from 4.97 billion units worth RM804.71 million in the previous week.
The ACE Market volume shrank to 9.52 billion shares valued at RM2.99 billion from 13.04 billion shares valued at RM3.31 billion previously.
Nevertheless, the local market snapped its losing streak on Wednesday as bargain-hunting emerged ahead of the long weekend break, on the promising news of COVID-19 vaccine delivery by pharmaceutical company, AstraZeneca, which is expected to take place in the first half of 2021.
I dream last night, old man told me vaccine tender by KKM will come out early january, if YT sole distributor for astrazeneca, maybe can get direct nego, other vaccine will be selective tender, few company will be ask for tender proposal... Early january is new financial year for gov... Using 2021 budget... As for pharmaniaga and dpharma under MOSTI khairy jamaludin is different story, under KKM gov want to purchase ready made vaccine ASAP. Dont believe me, its just a dream.
RM3 is too far...even if they get both government and private sector business, to reach RM3 will take at least another 3-5 years time, considering the number of vaccines they can sell under the exclusive deal. but short term TP 0.60 and 0.80 are more reasonable and mid term RM1.00 is good to have...
KUALA LUMPUR (REUTERS) - Malaysia said on Saturday (Dec 19) it has secured coronavirus vaccine from AstraZeneca PLC, on the heels of news it will receive the Pfizer-BioNTech vaccine in February as it grapples with a surge in infections.
The AstraZeneca deal, to be signed on Monday, will allow immunisation of about 20 per cent of Malaysia’s population of 32 million, similar to that of the deal with US giant Pfizer Inc and its German partner BioNTech SE, said Health Minister Adham Baba.
Any counters drop then the explanation in i3 would be big players wanna flush out contra and retailers and collect cheap tickets. LOL! Thats the only logic nowadays.
it's good to see the price moves like this.. volume gilak besar but price tak gerak langsung. the boss kawal ngan kuat, probably preventing it to goes up before something big that is coming soon.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
gateway31
333 posts
Posted by gateway31 > 2020-12-25 23:03 | Report Abuse
Google Translate:
Financial Associated Press (Shenzhen, reporter Ding Rong), Malaysian listed company YONGTAIBERHAD recently announced that the company has reached cooperation with Shenzhen Kangtai Biological Products Co., Ltd. and KLINSELSDNBHD to promote Kangtai Bio-New Crown inactivated vaccine in Malaysia to carry out phase III clinical trials . After the phase III clinical trial is successfully concluded or emergency use rights are obtained in Malaysia, the company will have the exclusive commercialization rights. The two parties plan to cooperate with about 100 million doses, a five-year vaccine procurement plan.
A person close to Kangtai Biologicals (300601.SZ) said: "At present, Kangtai Biologicals Covid-19 vaccine research and development continues to advance. This time, it is cooperating with Malaysia YONGTAIBERHAD to jointly promote the international multi-center phase III clinical trial of the new coronavirus inactivated vaccine."
Regarding the new coronavirus inactivated vaccine (Vero cell), Kangtai Biotechnology received a drug clinical trial approval document issued by the National Medical Products Administration in September this year. After review and review by a special expert group, the product was approved for clinical trials in an emergency. The indication is Prevent new coronavirus pneumonia caused by new coronavirus infection. Information from the China Clinical Trial Registration Center shows that the vaccine has entered the phase II clinical trial in October.
It is worth mentioning that in addition to the independently developed inactivated vaccine for the new crown, Kangtai Biotech also cooperates with AstraZeneca in the ChAdOx1 adenovirus vector vaccine. The viral vector COVID-19 vaccine developed by the company and AstraZeneca is currently in the phase III clinical trial. It is a rapidly progressing COVID-19 vaccine project in the world. It is expected to be used urgently in Europe and the United States by the end of the year. It is expected to be introduced to China in the future. The time for domestic clinical trials is expected. It will also be shortened. In addition, Kangtai Biological also deployed recombinant VSV virus vector vaccine.
The Financial Association stated: The content of the article is for reference only and does not constitute investment advice. Investors operate accordingly at their own risk.